Company Overview and News
A $218 million research organisation designed to develop mineral-discovery technologies has been launched by South Australian Energy and Mining Minister Dan van Holst Pellekaan.
AAUKF AAL NGLOY
LONDON, Oct 5 ― Britain's main stock index edged lower today and was poised for its biggest weekly drop in a month as a selloff in the global bond markets led by US Treasuries dampened appetite for riskier assets such as equities.
BAMGF INTU RIO RIO CCRGF AAL RTPPF AAUKF RIO RTNTF BAMKF NGLOY BAM
2018-10-03 proactiveinvestors.com.au - 1
PolarX Ltd’s (ASX:PXX) Alaska Range copper-gold-silver tenements are within a highly prospective area of Alaska but unlike a number of its well-known neighbours are on state mining claims, making them simpler to develop.
NDMWF ABX JPM AAUKF RICA NAK AAL CYY NG NGLOY RUFIF ABX
PRETORIA, Oct 2 (Reuters) - The diamond trade must confront its tarnished image and revamp its certification scheme or risk seeing increasingly demanding consumers spurn natural stones in favour of cheaper synthetic diamonds, a senior U.S. official said.
AAUKF AAL MS NGLOY
2018-10-01 seekingalpha - 7
Science and art, or if you prefer skill and luck, are both needed for consistent success in short-term trading to long-term investing. Some deny this and say it's all math, claiming that markets always represent fair value. If so, high-frequency trading algo-bot scalpers will always win, meaning people can never outsmart to beat the market as all opportunities and risks are fully discounted into prices.
STZ.B TWX MEAOF BTR AMZN AABA LVNSF FQM NDM MISVF HVBTF GDX AXXDF STZ TWC PRU SLV BABA ATUSF AAUKF VZ BALMF BB FB DB KGI.DB NFLX GOOG GLD TLRY ALS WEED NAK PMNXF AAPL FQVLF PRU ADV BLKCF DIS KL GDXJ EGO FM KGI MSV KGI.DB.A AAL CGC NDMWF ELD BAR NGLOY
2018-09-30 scmp - 2
AP Ventures, with US$200 million worth of assets under management, launches new fund to target investments in renewable energy-related projects
AAUKF 2338 WEICF JMPLY 3993 AAL JMPLF NGLOY WEICY BLDP
MILAN (Reuters) - The $40 billion takeover of British broadcaster Sky (SKYB.L) and other new deals in Europe have broken a summer lull to bolster investor optimism over an M&A revival in the region.
DB BLT RRS SCGLF MS ABX ABX AKZA BHPBF RGORF SCGLY AAL GOLD GOLD BHP AAUKF BBL BHP GLE BHPLF NGLOY
Serabi Gold plc (AIM:SRB, TSX:SBI), the Brazilian-focused gold mining and development company, is pleased to announce the appointment of Mr. Roney Almeida, to the newly established position of Chief Operating Officer. Mr. Almeida, a Brazilian national and resident in Belo Horizonte, Brazil, will report to Mr. Mike Hodgson, CEO of Serabi Gold plc.
SBI SRBIF SRBID AAUKF AAL SRB NGLOY
VANCOUVER, British Columbia, Sept. 19, 2018 (GLOBE NEWSWIRE) -- Group Ten Metals Inc. (TSX.V: PGE; OTC: PGEZF, FSE: 5D32) (the “Company” or “Group Ten”) announces the appointment of Dr. David Broughton Ph.D., P.Geo., as Senior Technical Advisor, with a primary focus on the Company’s flagship Stillwater West PGE-Ni-Cu project in Montana, USA.
IVPAF DCGCF PGE PGEZF AAUKF NCPCF IVN AAL SWC NGLOY
Several Year 11 and 12 students from Biloela and Moura in Queensland are to take part this week in an immersive trade careers camp set up by Anglo American and the Queensland Minerals and Energy Academy (QMEA), a partnership between the Queensland Government and Queensland Resources Council (QRC).
AAUKF AAL NGLOY
VANCOUVER, British Columbia, Sept. 14, 2018 (GLOBE NEWSWIRE) -- Q-Gold Resources Ltd. (the "Company") (TSX VENTURE: QGR) (http://www.qgoldresources.com) is pleased to announce that at the Annual and Special Meeting of shareholders (the “Meeting”) held on September 13, 2018, 100% of the shares at the Meeting voted for the re-election of Messrs. Fred Leigh and Robert C. Bryce as directors for the ensuing year and for the election of Mr.
CNR AAUKF AAL QGLDF NGLOY
Sept 14 (Reuters) - Chile’s congress is studying a proposal for an additional royalty payment for copper and lithium miners operating in the country to bolster the development of the regions around their deposits, according to a draft seen by Reuters.
BLT ALB ANTO BHPBF ANFGY AAL ANFGF BHP AAUKF BBL 70GD BHP BHPLF NGLOY
2018-10-01 - Asif
Overview The following discussion and analysis should be read in conjunction with its unaudited interim condensed consolidated financial statements and the related notes that appear elsewhere in this quarterly report on Form 10-Q. This discussion contains forward-looking statements reflecting its current expectations that involve risks and uncertainties. Actual results may differ materially from those discussed in these forward-looking statements due to a number of factors, including those set forth in the section entitled “Risk Factors” in its most recent annual report on Form 10-K. For further information regarding forward-looking statements, please refer to the “Special Note Regarding Forward-Looking Statements and Projections” immediately after the index to this quarterly report on Form 10-Q. Alimera Sciences, Inc., and its subsidiaries (we or Alimera), is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharma...
2018-09-25 - Asif
Background DelMar Pharmaceuticals, Inc. is a clinical stage drug development company with a focus on the treatment of cancer. The company's mission is to benefit patients and create shareholder value by developing and commercializing anti-cancer therapies for patients whose tumors exhibit features that make them resistant to, or unlikely to respond to, currently available therapies, particularly for orphan cancer indications where patients have failed, or are unlikely to respond to, currently available therapy. DelMar Pharmaceuticals is developing VAL-083, a novel, DNA-targeting agent, for the treatment of glioblastoma multiforme (“GBM”) and potentially other solid tumors, including ovarian cancer. VAL-083 is a first-in-class, DNA-targeting chemotherapeutic that demonstrated activity against a range of tumor types in prior Phase 1 and Phase 2 clinical studies sponsored by the US National Cancer Institute (“NCI”). The company's recent research has highlighted the opportunit...
2018-09-18 - Asif
Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...
Silicon Investor Message Boards
This table lists all message boards related to LSE:AAL / ANGLO AMERICAN on message board site Silicon Investor.